Chandigarh, August 27, 2020: World-wide, there are nearly 2.5 crore Coronavirus cases as on today with over 8 lakh fatalities.
Among the Vaccines being developed across the world, the Oxford COVID-19 vaccine team is working at an unprecedented speed in a race against this global threat to human health.
At many locations in the world, researchers started screening healthy volunteers aged 18-55 in March and in India trials started recently including at PGI, Chandigarh.
It is reported that the second phase of trials will start in PGI Chandigarh in early September. It seems that the Institute has received approval from its internal ethical committee and is waiting the signing of the agreement between the Indian Council of Medical Research and Serum Institute of India.
The Phase II trials will be conducted over four weeks on around 250 candidates.
Meanwhile, in another world-wide research move, seventy-five countries submitted their expression of interest to a COVAX Facility, according to WHO.
The 75 countries, which would finance the vaccines from their own public finance budgets, partner with up to 90 lower-income countries that could be supported through voluntary donations to Gavi’s COVAX Advance Market Commitment (AMC). Together, this group of up to 165 countries represents more than 60% of the world’s population.
The COVAX Facility, and the AMC within it, is designed to guarantee rapid, fair and equitable access to COVID -19 vaccines for every country in the world, rich and poor.
According to Dr Soumya Swaminathan, WHO Chief Scientist. “A vaccine that is affordable and accessible to all will help us address systemic health inequalities. We need all countries to sup-port COVAX to achieve this goal.”